BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29178020)

  • 1. Author Correction: A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):309. PubMed ID: 29178020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
    Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
    J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triggering final oocyte maturation using different doses of human chorionic gonadotropin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone.
    Kolibianakis EM; Papanikolaou EG; Tournaye H; Camus M; Van Steirteghem AC; Devroey P
    Fertil Steril; 2007 Nov; 88(5):1382-8. PubMed ID: 17445806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial.
    Mai Q; Hu X; Yang G; Luo Y; Huang K; Yuan Y; Zhou C
    Am J Obstet Gynecol; 2017 Jan; 216(1):42.e1-42.e10. PubMed ID: 27555316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
    European Recombinant LH Study Group
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger).
    Oliveira SA; Calsavara VF; Cortés GC
    JBRA Assist Reprod; 2016 Dec; 20(4):246-250. PubMed ID: 28050961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve.
    Lin MH; Wu FS; Hwu YM; Lee RK; Li RS; Li SH
    Reprod Biol Endocrinol; 2019 Jan; 17(1):7. PubMed ID: 30609935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic understanding of gonadotropin-releasing hormone-agonist triggering.
    Casper RF
    Fertil Steril; 2015 Apr; 103(4):867-9. PubMed ID: 25712575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization.
    Fauser BC; de Jong D; Olivennes F; Wramsby H; Tay C; Itskovitz-Eldor J; van Hooren HG
    J Clin Endocrinol Metab; 2002 Feb; 87(2):709-15. PubMed ID: 11836309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety.
    Ashrafi M; Kiani K; Ghasemi A; Rastegar F; Nabavi M
    Arch Gynecol Obstet; 2011 Dec; 284(6):1431-8. PubMed ID: 21210134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard human chorionic gonadotropin versus double trigger for final oocyte maturation results in different granulosa cells gene expressions: a pilot study.
    Haas J; Ophir L; Barzilay E; Machtinger R; Yung Y; Orvieto R; Hourvitz A
    Fertil Steril; 2016 Sep; 106(3):653-659.e1. PubMed ID: 27341989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.